These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2391188)

  • 1. Combined effects of intraperitoneal administration of recombinant interleukin-2 and streptococcal preparation OK-432 in murine tumors.
    Fujioka T; Ishikura K; Tanji S; Okamoto T; Koike H; Aoki H; Ohhori T; Kubo T
    Int J Immunopharmacol; 1990; 12(4):419-26. PubMed ID: 2391188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Combined effect of intraperitoneally administered OK-432 and recombinant interleukin (rIL-2) against mouse tumors].
    Fujioka T; Shiraishi M; Tanji S; Koike H; Kumagai K; Kubo T; Ohhori T
    Nihon Gan Chiryo Gakkai Shi; 1989 May; 24(5):948-56. PubMed ID: 2789265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pronounced antitumor effect of LAK-like cells induced in the peritoneal cavity of mice after intraperitoneal injection of OK-432, a killed streptococcal preparation.
    Saito M; Ichimura O; Kataoka M; Moriya Y; Ueno K; Sugawara Y; Nanjo M; Ishida N
    Cancer Immunol Immunother; 1986; 22(3):161-8. PubMed ID: 2425968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of biological response modifiers on a spontaneous murine renal cell carcinoma regression of metastases caused by the streptococcal preparation OK-432].
    Tanji S
    Nihon Hinyokika Gakkai Zasshi; 1991 May; 82(5):716-25. PubMed ID: 1875566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2.
    Hinuma S; Naruo K; Shiho O; Tsukamoto K
    Immunology; 1986 Oct; 59(2):251-9. PubMed ID: 3490435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection and characterization of anti-tumour effector cells in Meth-A-bearing mice treated with recombinant human interleukin 2.
    Naruo KI; Hinuma S; Shiho O; Houkan T; Ootsu K; Tsukamoto K
    Clin Exp Immunol; 1989 May; 76(2):278-83. PubMed ID: 2788049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marked reduction of subcutaneous tumor growth by intraperitoneal administration of recombinant human interleukin 2 with a cell accumulator, proteose-peptone, in mice.
    Tanida S; Uchida H; Taniguchi K; Nomoto K
    Cancer Res; 1989 Jan; 49(2):284-8. PubMed ID: 2783379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of LAK-like activity and cytokine induction in regional lymph nodes and spleen cells of mice after intralymphnodal injection of OK-432, a killed streptococcal preparation.
    Sakakura C; Takahashi T; Hagiwara A; Yamane T; Sawai S; Okano S; Ozaki K; Sasaki S; Tsujimoto H
    Anticancer Drugs; 1993 Jun; 4(3):381-8. PubMed ID: 8358067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of antitumor effects of OK-432 against syngeneic mouse fibrosarcoma: combination effect of OK-432 and recombinant lymphokines.
    Nanjo M; Moriya Y; Hashimoto S; Kataoka M; Saito M; Yoshida T; Ishida N
    Int J Immunopharmacol; 1991; 13(2-3):205-15. PubMed ID: 1906439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors.
    Maekawa R; Kitagawa T; Koizumi K; Sato K; Homma M
    J Biol Response Mod; 1989 Dec; 8(6):676-90. PubMed ID: 2600605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive immunotherapy in tumor-bearing mice with OK-432-induced killer cells.
    Ujiie T
    Jpn J Exp Med; 1988 Apr; 58(2):109-14. PubMed ID: 3261814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic T-cell-mediated antitumor effect of levamisole against murine syngeneic fibrosarcoma.
    Gomi K; Morimoto M; Nomoto K
    Cancer Res; 1982 Oct; 42(10):4197-202. PubMed ID: 6980702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice.
    Hirahara N; Nio Y; Sasaki S; Minari Y; Takamura M; Iguchi C; Dong M; Yamasawa K; Tamura K
    Oncology; 2001; 61(1):79-89. PubMed ID: 11474253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmentation of mouse natural killer cell activity by combined hyperthermia and streptococcal preparation, OK-432 (Picibanil) treatment.
    Taradi M; Urano M; Taradi SK; Maruyama Y
    Int J Hyperthermia; 1991; 7(4):653-65. PubMed ID: 1919160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination treatment with irritant and recombinant interleukin 2 in the peritoneal cavity for evoking effective anti-tumor activity: generation of lymphokine-activated killer cells and tumor-specific killer cells.
    Uchida H; Taniguchi K; Nomoto K
    Jpn J Cancer Res; 1990 Apr; 81(4):416-24. PubMed ID: 2114394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine-inducing activity and antitumor effect of a liposome-incorporated interferon-gamma-inducing molecule derived from OK-432, a streptococcal preparation.
    Okamoto M; Gohda H; Ohe G; Yoshida H; Matsuno T; Saito M; Sato M
    J Immunother; 2000 Jan; 23(1):94-103. PubMed ID: 10687142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anticancer effects of OK-432 (2). Anticancer actions of M phi activated by OK-432].
    Saito M; Aonuma E; Noda T; Nakadate I; Nanjo M; Ebina T; Ishida N
    Gan To Kagaku Ryoho; 1983 May; 10(5):1363-71. PubMed ID: 6870302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cure of human melanoma lung metastases in nude mice with chronic indomethacin therapy combined with multiple rounds of IL-2: characteristics of killer cells generated in situ.
    Lala PK; Elkashab M; Kerbel RS; Parhar RS
    Int Immunol; 1990; 2(12):1149-58. PubMed ID: 2090199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmentation of mouse natural killer cell activity by a streptococcal preparation, OK-432.
    Oshimi K; Kano S; Takaku F; Okumura K
    J Natl Cancer Inst; 1980 Dec; 65(6):1265-9. PubMed ID: 7001124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.